Related Experiment Video
Updated: Feb 25, 2026
08:36
Collecting Sleep, Circadian, Fatigue, and Performance Data in Complex Operational Environments
Published on: August 8, 2019
12.9K
Nonpharmacologic Management of Excessive Daytime Sleepiness.
1Department of Neurology, Center for Sleep Medicine, Weill Cornell Medical College of Cornell University, 425 East 61st Street, 5th Floor, New York, NY 10065, USA.
Sleep Medicine Clinics
|August 6, 2017
Summary
This review focuses on non-drug treatments for primary excessive daytime sleepiness. It discusses optimal sleep and introduces a novel behavioral approach for managing daytime somnolence.
Area of Science:
- Sleep Medicine
- Behavioral Science
Background:
- Excessive daytime sleepiness (EDS) is often secondary to other conditions, but primary EDS requires distinct management strategies.
- Optimal sleep duration, insufficiency, and individual sleep needs are crucial factors in understanding and addressing primary EDS.
- Existing literature often overlooks non-pharmacologic interventions for primary EDS.
Purpose of the Study:
- To review and synthesize non-pharmacologic treatments for primary excessive daytime sleepiness.
- To provide a comprehensive background on optimal sleep parameters relevant to EDS.
- To propose and describe a novel behavioral intervention for daytime somnolence.
Main Methods:
- Literature review focusing on non-pharmacologic interventions for primary EDS.
- Detailed discussion of optimal sleep duration, insufficiency, and sleep need.
- Examination of behavioral strategies, including sleep banking and a newly proposed method.
Main Results:
- Non-pharmacologic approaches are viable for managing primary EDS.
- Understanding sleep needs is fundamental to addressing daytime sleepiness.
- A novel behavioral method for treating daytime somnolence has been developed.
Conclusions:
- Primary excessive daytime sleepiness can be effectively managed through behavioral interventions.
- The proposed novel behavioral method offers a new avenue for treating daytime somnolence.
- Further research into non-pharmacologic strategies is warranted for EDS management.
Related Concept Videos
01:19Management of Insomnia
732
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
732
01:13Insufficient Sleep and Sleep Deprivation
978
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
978
01:07Narcolepsy
622
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
622
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
689
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
689
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
423
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
423
01:27Insomnia
515
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
515